1991 – Started as Intermed Pharma to manufacture of intermediates.
2006 – Commenced manufacturing 1st Oncology API (Capecitabine).
2007 – Commenced manufacturing of 1st General API (Efavirenz).
2009 – Company name changed as Cdymax (India) Pharma Pvt. Ltd.
2011 – New Production Block (PB-2) commissioned to manufacture of Oncology APIs.
2013 – Received approval from WHO Geneva for Efavirenz.
2014 – Received approval from WHO Geneva for Tenofovir Disoproxil Fumarate.
2014 – Received approval from WHO Geneva for Lopinavir.
2014 – CEP for Capecitabine from EDQM.
2015 – Received facility approval from USFDA for Tenofovir DF and Efavirenz.
2017 – Received facility approval from Russian Regulatory for Capecitabine.
2019 – COFEPRIS – Mexican Authority Audited the oncology facility for the product Erlotinib HCl.
2019 – USFDA approved the oncology facility for the product Palbociclib.
2019 – WHO audited the facility for the products Tenofovir Disoproxil Fumarate, Atazanavir Sulphate and Efavirenz.